132 related articles for article (PubMed ID: 8609229)
1. Early and advanced glycosylation end products. Kinetics of formation and clearance in peritoneal dialysis.
Friedlander MA; Wu YC; Elgawish A; Monnier VM
J Clin Invest; 1996 Feb; 97(3):728-35. PubMed ID: 8609229
[TBL] [Abstract][Full Text] [Related]
2. Kinetic analysis of furosine and pentosidine in CAPD patients.
Kumano K; Yokota S; Sakai T; Kobayashi N; Yoshida A; Yoshihara T; Shibata K; Izumi G; Wang H
Adv Perit Dial; 1997; 13():53-7. PubMed ID: 9360651
[TBL] [Abstract][Full Text] [Related]
3. Advanced glycation and lipidoxidation of the peritoneal membrane: respective roles of serum and peritoneal fluid reactive carbonyl compounds.
Miyata T; Horie K; Ueda Y; Fujita Y; Izuhara Y; Hirano H; Uchida K; Saito A; van Ypersele de Strihou C; Kurokawa K
Kidney Int; 2000 Jul; 58(1):425-35. PubMed ID: 10886591
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo generation and kinetics of glycosylation products in peritoneal dialysis effluents.
Yokota S; Kumano K; Hyodo T; Sakai T; Izumi G; Hashimoto A; Shibata K; Wang H
Adv Perit Dial; 1998; 14():195-9. PubMed ID: 10649723
[TBL] [Abstract][Full Text] [Related]
5. Effect of dwell time on carbonyl stress using icodextrin and amino acid peritoneal dialysis fluids.
Ueda Y; Miyata T; Goffin E; Yoshino A; Inagi R; Ishibashi Y; Izuhara Y; Saito A; Kurokawa K; Van Ypersele De Strihou C
Kidney Int; 2000 Dec; 58(6):2518-24. PubMed ID: 11115086
[TBL] [Abstract][Full Text] [Related]
6. Effect of the peritoneal dialysis prescription on pentosidine in children.
Bayazit AK; Vogt BA; Dell KM; Davis ID; Noyan A; Anarat A; Avner ED; Erhard P; Weiss MF
Pediatr Nephrol; 2003 Oct; 18(10):1049-54. PubMed ID: 12898376
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms for the formation of glycoxidation products in end-stage renal disease.
Weiss MF; Erhard P; Kader-Attia FA; Wu YC; Deoreo PB; Araki A; Glomb MA; Monnier VM
Kidney Int; 2000 Jun; 57(6):2571-85. PubMed ID: 10844627
[TBL] [Abstract][Full Text] [Related]
8. Clearance of pentosidine, an advanced glycation end product, by different modalities of renal replacement therapy.
Miyata T; Ueda Y; Yoshida A; Sugiyama S; Iida Y; Jadoul M; Maeda K; Kurokawa K; van Ypersele de Strihou C
Kidney Int; 1997 Mar; 51(3):880-7. PubMed ID: 9067925
[TBL] [Abstract][Full Text] [Related]
9. Association between Asymmetric Dimethylarginine and Pentosidine in Dialysis Effluent of Peritoneal Dialysis Patients -A possible intraperitoneal crosstalk between asymmetric dimethylarginine and advanced glycation end products in peritoneal dialysis patients.
Ishida M; Kakuta T; Miyakogawa T; Tatsumi R; Matsumoto C; Fukagawa M
Tokai J Exp Clin Med; 2016 Jun; 41(2):97-100. PubMed ID: 27345001
[TBL] [Abstract][Full Text] [Related]
10. Analysis of non enzymatic glycosylation in vivo: impact of different dialysis solutions.
Ho-dac-Pannekeet MM; Weiss MF; de Waart DR; Erhard P; Hiralall JK; Krediet RT
Perit Dial Int; 1999; 19 Suppl 2():S68-74. PubMed ID: 10406497
[TBL] [Abstract][Full Text] [Related]
11. The advanced glycation endproduct pentosidine and monocyte activation in uremia.
Friedlander MA; Witko-Sarsat V; Nguyen AT; Wu YC; Labrunte M; Verger C; Jungers P; Descamps-Latscha B
Clin Nephrol; 1996 Jun; 45(6):379-82. PubMed ID: 8793229
[TBL] [Abstract][Full Text] [Related]
12. Advanced glycation end product free adducts are cleared by dialysis.
Agalou S; Ahmed N; Thornalley PJ; Dawnay A
Ann N Y Acad Sci; 2005 Jun; 1043():734-9. PubMed ID: 16037300
[TBL] [Abstract][Full Text] [Related]
13. Disparate changes in plasma and tissue pentosidine levels after kidney and kidney-pancreas transplantation.
Hricik DE; Wu YC; Schulak A; Friedlander MA
Clin Transplant; 1996 Dec; 10(6 Pt 1):568-73. PubMed ID: 8996781
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of advanced glycation end products and carbonyl compounds in patients with different conditions of oxidative stress.
Lapolla A; Reitano R; Seraglia R; Sartore G; Ragazzi E; Traldi P
Mol Nutr Food Res; 2005 Jul; 49(7):685-90. PubMed ID: 15926142
[TBL] [Abstract][Full Text] [Related]
15. Influence of dialysis modality on plasma and tissue concentrations of pentosidine in patients with end-stage renal disease.
Friedlander MA; Wu YC; Schulak JA; Monnier VM; Hricik DE
Am J Kidney Dis; 1995 Mar; 25(3):445-51. PubMed ID: 7872323
[TBL] [Abstract][Full Text] [Related]
16. Influence of hemodialysis membrane type on pentosidine plasma level, a marker of "carbonyl stress".
Jadoul M; Ueda Y; Yasuda Y; Saito A; Robert A; Ishida N; Kurokawa K; Van Ypersele De Strihou C; Miyata T
Kidney Int; 1999 Jun; 55(6):2487-92. PubMed ID: 10354298
[TBL] [Abstract][Full Text] [Related]
17. Profound mishandling of protein glycation degradation products in uremia and dialysis.
Agalou S; Ahmed N; Babaei-Jadidi R; Dawnay A; Thornalley PJ
J Am Soc Nephrol; 2005 May; 16(5):1471-85. PubMed ID: 15800128
[TBL] [Abstract][Full Text] [Related]
18. Accumulation of tissue advanced glycation end products correlated with glucose exposure dose and associated with cardiovascular morbidity in patients on peritoneal dialysis.
Jiang J; Chen P; Chen J; Yu X; Xie D; Mei C; Xiong F; Shi W; Zhou W; Liu X; Sun S; Zhang P; Yang X; Zhang Y; Zhang Y; Liang X; Zhang Z; Lin Q; Yu Y; Miyata T; Tian J; Liang M; Luo W; Xu X; Hou F
Atherosclerosis; 2012 Sep; 224(1):187-94. PubMed ID: 22857897
[TBL] [Abstract][Full Text] [Related]
19. Plasma Pentosidine and Its Association with Mortality in Patients with Chronic Kidney Disease.
Machowska A; Sun J; Qureshi AR; Isoyama N; Leurs P; Anderstam B; Heimburger O; Barany P; Stenvinkel P; Lindholm B
PLoS One; 2016; 11(10):e0163826. PubMed ID: 27701453
[TBL] [Abstract][Full Text] [Related]
20. Removal of advanced glycation end products in clinical renal failure by peritoneal dialysis and haemodialysis.
Agalou S; Ahmed N; Dawnay A; Thornalley PJ
Biochem Soc Trans; 2003 Dec; 31(Pt 6):1394-6. PubMed ID: 14641071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
